Table 1.
Population-based and clinical samples
| Sample | Source | Ethnicity | Number | Phenotype/diagnosis |
|---|---|---|---|---|
| ALSPACa,b | General population | White European | 5612 (7 y): age(SE) = 6.79(0.11) | ADHD symptoms (mother-report) as assessed with SDQ ADHD scores |
| 5678 (10 y): age(SE) = 9.65(0.12) | ||||
| 5259 (12 y): age(SE) = 11.72(0.13) | ||||
| 5072 (13 y): age(SE) = 13.16(0.18) | ||||
| 4164 (17 y): age(SE) = 16.84(0.18) | ||||
| ALSPACa,b | General population | White European | 5551 (8 y): age(SE) = 7.65(0.14) | Social-communication difficulties (mother-report) as assessed with SCDC scores |
| 5460 (11 y): age(SE) = 10.72(0.13) | ||||
| 5060 (14 y): age(SE) = 13.90(0.15) | ||||
| 4174 (17 y): age (SE) = 16.84(0.36) | ||||
| PGC-ADHDc | Clinical ADHD sample | White European | 4163 cases and 12,040 controls/pseudo-controls | ADHD or hyperkinetic disorder |
| PGC-ASDa | Clinical ASD sample | White European | 5305 cases; 5305 pseudo-controls | ASD |
ADHD attention deficit hyperactivity disorder, ALSPAC Avon Longitudinal study of Parents and Children, ASD autism spectrum disorder, PGC-ADHD ADHD collection of the Psychiatric Genomics Consortium (PGC), PGC-ASD ASD collection of the PGC, SCDC Social and Communication Disorders Checklist, SDQ-ADHD ADHD subscale of the Strength and Difficulties Questionnaire, y age in years
aSamples were imputed to a 1000 genomes reference (Phase1_v3)
bALSPAC individuals who were related to participants of the PGC-ADHD sample were excluded
cSamples were imputed to HapMap3 CEU and TSI